San Diego-centered Viking Therapeutics marked alone as a serious competitor inside the weight loss drug marketplace in February after revealing promising knowledge from a mid-stage trial of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when provided being a weekly injection and in March the company